866-997-4948(US-Canada Toll Free)

Thrombocytopenia - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 163 Pages

Thrombocytopenia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombocytopenia Pipeline Review, H2 2016, provides an overview of the Thrombocytopenia (Hematological Disorders) pipeline landscape.

Thrombocytopenia is characterized by an abnormally low amount of platelets Low platelet levels occur due to less production of platelets in the bone marrow, increased breakdown of platelets in the bloodstream or in the spleen or liver. Symptoms include bleeding in the mouth and gums, bruising, nosebleeds and rashes. Treatment includes transfusion of platelets to stop or prevent bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombocytopenia Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Thrombocytopenia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thrombocytopenia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombocytopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 10, 6, 1, 13 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Thrombocytopenia.

Thrombocytopenia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombocytopenia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Thrombocytopenia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thrombocytopenia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thrombocytopenia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Thrombocytopenia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thrombocytopenia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thrombocytopenia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thrombocytopenia Overview 8
Therapeutics Development 9
Pipeline Products for Thrombocytopenia - Overview 9
Pipeline Products for Thrombocytopenia - Comparative Analysis 10
Thrombocytopenia - Therapeutics under Development by Companies 11
Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 13
Thrombocytopenia - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Thrombocytopenia - Products under Development by Companies 17
Thrombocytopenia - Products under Investigation by Universities/Institutes 20
Thrombocytopenia - Companies Involved in Therapeutics Development 21
3SBio Inc. 21
AkaRx Inc 22
Amarillo Biosciences, Inc. 23
Amgen Inc. 24
arGEN-X BV 25
BioLineRx, Ltd. 26
Biotest AG 27
Boehringer Ingelheim GmbH 28
Bolder Biotechnology, Inc. 29
Bristol-Myers Squibb Company 30
Cellerant Therapeutics, Inc. 31
Genosco 32
Hansa Medical AB 33
Immunomedics, Inc. 34
Intas Pharmaceuticals Ltd. 35
Jiangsu Hengrui Medicine Co., Ltd. 36
Merck & Co., Inc. 37
Momenta Pharmaceuticals, Inc. 38
Myelo Therapeutics GmbH 39
Neumedicines Inc. 40
Novartis AG 41
Pfizer Inc. 42
PhytoHealth Corporation 43
Prophylix Pharma AS 44
Protalex, Inc. 45
Rigel Pharmaceuticals, Inc. 46
Shionogi & Co., Ltd. 47
Shire Plc 48
STATegics, Inc. 49
UCB SA 50
ViroMed Co Ltd 51
Thrombocytopenia - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 61
ARGX-113 - Drug Profile 62
avatrombopag - Drug Profile 64
BBT-059 - Drug Profile 66
BI-655064 - Drug Profile 67
BL-8040 - Drug Profile 69
BMS-986004 - Drug Profile 80
BT-595 - Drug Profile 81
CLT-009 - Drug Profile 82
eltrombopag olamine - Drug Profile 83
eltrombopag olamine - Drug Profile 89
fostamatinib disodium - Drug Profile 90
GL-2045 - Drug Profile 96
GSK-2285921 - Drug Profile 97
Hetrombopag Olamine - Drug Profile 99
interferon alfa - Drug Profile 100
lusutrombopag - Drug Profile 102
M-281 - Drug Profile 103
MK-8723 - Drug Profile 104
Monoclonal Antibody to Agonize Thrombopoietin Receptor for Thrombocytopenia - Drug Profile 105
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 106
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 107
Myelo-001 - Drug Profile 108
NMIL-121 - Drug Profile 109
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia and Anemia - Drug Profile 112
PEG-VM501 - Drug Profile 113
PHN-013 - Drug Profile 114
PRTX-100 - Drug Profile 115
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 122
romiplostim - Drug Profile 123
romiplostim biosimilar - Drug Profile 126
SHP-652 - Drug Profile 127
SKIO-703 - Drug Profile 130
Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 131
Small Molecules to Inhibit PF4 for Heparin Induced Thrombocytopenia - Drug Profile 132
STST-4 - Drug Profile 133
thrombopoietin - Drug Profile 134
Tromplate - Drug Profile 135
TXA-302 - Drug Profile 136
UCB-7665 - Drug Profile 137
veltuzumab - Drug Profile 138
Thrombocytopenia - Dormant Projects 142
Thrombocytopenia - Discontinued Products 145
Thrombocytopenia - Product Development Milestones 146
Featured News & Press Releases 146
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

List of Tables
Number of Products under Development for Thrombocytopenia, H2 2016 12
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Number of Products under Development by Companies, H2 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Development by Companies, H2 2016 (Contd..2) 22
Products under Investigation by Universities/Institutes, H2 2016 23
Thrombocytopenia - Pipeline by 3SBio Inc., H2 2016 24
Thrombocytopenia - Pipeline by AkaRx Inc, H2 2016 25
Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2016 26
Thrombocytopenia - Pipeline by Amgen Inc., H2 2016 27
Thrombocytopenia - Pipeline by arGEN-X BV, H2 2016 28
Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2016 29
Thrombocytopenia - Pipeline by Biotest AG, H2 2016 30
Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 31
Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2016 32
Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2016 33
Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2016 34
Thrombocytopenia - Pipeline by Genosco, H2 2016 35
Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2016 36
Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2016 37
Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 38
Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 39
Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2016 40
Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 41
Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2016 42
Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2016 43
Thrombocytopenia - Pipeline by Novartis AG, H2 2016 44
Thrombocytopenia - Pipeline by Pfizer Inc., H2 2016 45
Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2016 46
Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2016 47
Thrombocytopenia - Pipeline by Protalex, Inc., H2 2016 48
Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 49
Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2016 50
Thrombocytopenia - Pipeline by Shire Plc, H2 2016 51
Thrombocytopenia - Pipeline by STATegics, Inc., H2 2016 52
Thrombocytopenia - Pipeline by UCB SA, H2 2016 53
Thrombocytopenia - Pipeline by ViroMed Co Ltd, H2 2016 54
Assessment by Monotherapy Products, H2 2016 55
Number of Products by Stage and Target, H2 2016 57
Number of Products by Stage and Mechanism of Action, H2 2016 59
Number of Products by Stage and Route of Administration, H2 2016 61
Number of Products by Stage and Molecule Type, H2 2016 63
Thrombocytopenia - Dormant Projects, H2 2016 145
Thrombocytopenia - Dormant Projects (Contd..1), H2 2016 146
Thrombocytopenia - Dormant Projects (Contd..2), H2 2016 147
Thrombocytopenia - Discontinued Products, H2 2016 148

List of Figures
Number of Products under Development for Thrombocytopenia, H2 2016 12
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 17
Comparative Analysis by Clinical Stage Development, H2 2016 18
Comparative Analysis by Early Stage Products, H2 2016 19
Assessment by Monotherapy Products, H2 2016 55
Number of Products by Top 10 Targets, H2 2016 56
Number of Products by Stage and Top 10 Targets, H2 2016 56
Number of Products by Top 10 Mechanism of Actions, H2 2016 58
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 58
Number of Products by Routes of Administration, H2 2016 60
Number of Products by Stage and Routes of Administration, H2 2016 60
Number of Products by Top 10 Molecule Types, H2 2016 62
Number of Products by Stage and Top 10 Molecule Types, H2 2016 62

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *